Cristina Sampaio

Chief Medical Officer

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Cristina Sampaio is the Chief Medical Officer at CHDI Management and CHDI Foundation in the United States. Her research focuses on Alzheimer's disease, Huntington disease, and Parkinson's disease, particularly in the areas of clinical relevance of therapeutic interventions, disease progression modeling, and patient-reported outcome measures. She has authored several notable articles discussing the complexities of neurodegenerative diseases and their treatment paradigms.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (4)

Sarah J. Tabrizi

UNITED KINGDOM

View details

Sheng Luo

Duke University

UNITED STATES

View details

Tiago A. Mestre

CANADA

View details

Jeffrey Long

University of Iowa Healthcare

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Cristina Sampaio

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions

Not a slam dunk (or Free Lunch): The complex future of Alzheimer's combination therapy

Modeling Disease Progression and Placebo Response in Huntington Disease

Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington’s disease

Is Parkinson Disease Better Defined Solely by Biology or as a Clinical–Biological Entity? Lessons to be Learned from Alzheimer's Disease on Biological Definition and Staging

Time to Functional Loss as an Endpoint in Huntington's Disease Trials: Enrichment and Sample Size

Huntington disease – Update on ongoing therapeutic developments and a look toward the future

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

FDA Boosts the Progressive Supranuclear Palsy Rating Scale!

Defining Clinical Meaningfulness in Huntington's Disease

Reply to: “The Framework for Diagnostic Criteria in Movement Disorders: The Value of Methodological Tools and Combined Criteria”

A Unified Framework for Evidence‐Based Diagnostic Criteria Programs in Movement Disorders

A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study

Facilitating Huntington's disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1

Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”

Predictive Modeling of Huntington's Disease Unfolds Thalamic and Caudate Atrophy Dissociation

Collaborators (4)

Sarah J. Tabrizi

Sheng Luo

Tiago A. Mestre

Jeffrey Long

Make your next move.